SCH 13521 in the treatment of advanced carcinoma of the prostate.
D000368:Aged; D000726:Androgen Antagonists; D000813:Anilides / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity; D002277:Carcinoma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006177:Gynecomastia / Q000139:chemically induced; D006801:Humans; D006845:Hydrocarbons, Fluorinated / Q000627:therapeutic use; D006869:Hydronephrosis / Q000000981:diagnostic imaging; D007457:Iodine Radioisotopes; D007668:Kidney / Q000000981:diagnostic imaging; D008099:Liver; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009574:Nitro Compounds / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy; D010166:Palliative Care; D010919:Placebos; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011859:Radiography; D011877:Radionuclide Imaging; D012075:Remission, Spontaneous; D013667:Technetium; D013997:Time Factors
D000726:Androgen Antagonists; D000813:Anilides; D000970:Antineoplastic Agents; D006845:Hydrocarbons, Fluorinated; D007457:Iodine Radioisotopes; D009574:Nitro Compounds; D010919:Placebos; D013667:Technetium